Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds

Evolutionary perspectives

Felipe N. Albuquerque, Anna Bortnick, Javaid Iqbal, Yuki Ishibashi, Gregg W. Stone, Patrick W. Serruys

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Dual antiplatelet therapy reduces the risk of myocardial infarction, stent thrombosis, and cardiovascular mortality after percutaneous coronary intervention, but the optimal duration of therapy remains unclear. Stent thrombosis, one of the most feared complications of coronary intervention, is associated with high mortality and morbidity and is related in part to technical and patient-specific factors. Advances in device technology and better understanding of the pathophysiology of stent thrombosis have reduced the frequency of this devastating complication. Bioresorbable vascular scaffolds possess a number of advantageous features and are currently undergoing active investigation. Bioresorbable vascular scaffolds have been demonstrated to restore physiologic vasomotion, allow for late lumen enlargement, and upon full resorption remove the nidus for very late polymer reactions and resolve concerns of stent malapposition and side branch jailing. Based on the results from recent large-scale randomized trials, the optimal duration of dual antiplatelet therapy may depend on the choice of device type, as well as the individual patient risk of ischemic versus hemorrhagic complications.

Original languageEnglish (US)
JournalCatheterization and Cardiovascular Interventions
DOIs
StateAccepted/In press - 2015

Fingerprint

Drug-Eluting Stents
Platelet Aggregation Inhibitors
Stents
Blood Vessels
Thrombosis
Equipment and Supplies
Mortality
Percutaneous Coronary Intervention
Therapeutics
Polymers
Myocardial Infarction
Technology
Morbidity

Keywords

  • Bioresorbable vascular scaffolds
  • Dual anti-platelet therapy
  • Stent thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds : Evolutionary perspectives. / Albuquerque, Felipe N.; Bortnick, Anna; Iqbal, Javaid; Ishibashi, Yuki; Stone, Gregg W.; Serruys, Patrick W.

In: Catheterization and Cardiovascular Interventions, 2015.

Research output: Contribution to journalArticle

@article{25ea77fa6f4d4bf0a0a1fff6f1b1d5d7,
title = "Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives",
abstract = "Dual antiplatelet therapy reduces the risk of myocardial infarction, stent thrombosis, and cardiovascular mortality after percutaneous coronary intervention, but the optimal duration of therapy remains unclear. Stent thrombosis, one of the most feared complications of coronary intervention, is associated with high mortality and morbidity and is related in part to technical and patient-specific factors. Advances in device technology and better understanding of the pathophysiology of stent thrombosis have reduced the frequency of this devastating complication. Bioresorbable vascular scaffolds possess a number of advantageous features and are currently undergoing active investigation. Bioresorbable vascular scaffolds have been demonstrated to restore physiologic vasomotion, allow for late lumen enlargement, and upon full resorption remove the nidus for very late polymer reactions and resolve concerns of stent malapposition and side branch jailing. Based on the results from recent large-scale randomized trials, the optimal duration of dual antiplatelet therapy may depend on the choice of device type, as well as the individual patient risk of ischemic versus hemorrhagic complications.",
keywords = "Bioresorbable vascular scaffolds, Dual anti-platelet therapy, Stent thrombosis",
author = "Albuquerque, {Felipe N.} and Anna Bortnick and Javaid Iqbal and Yuki Ishibashi and Stone, {Gregg W.} and Serruys, {Patrick W.}",
year = "2015",
doi = "10.1002/ccd.26099",
language = "English (US)",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds

T2 - Evolutionary perspectives

AU - Albuquerque, Felipe N.

AU - Bortnick, Anna

AU - Iqbal, Javaid

AU - Ishibashi, Yuki

AU - Stone, Gregg W.

AU - Serruys, Patrick W.

PY - 2015

Y1 - 2015

N2 - Dual antiplatelet therapy reduces the risk of myocardial infarction, stent thrombosis, and cardiovascular mortality after percutaneous coronary intervention, but the optimal duration of therapy remains unclear. Stent thrombosis, one of the most feared complications of coronary intervention, is associated with high mortality and morbidity and is related in part to technical and patient-specific factors. Advances in device technology and better understanding of the pathophysiology of stent thrombosis have reduced the frequency of this devastating complication. Bioresorbable vascular scaffolds possess a number of advantageous features and are currently undergoing active investigation. Bioresorbable vascular scaffolds have been demonstrated to restore physiologic vasomotion, allow for late lumen enlargement, and upon full resorption remove the nidus for very late polymer reactions and resolve concerns of stent malapposition and side branch jailing. Based on the results from recent large-scale randomized trials, the optimal duration of dual antiplatelet therapy may depend on the choice of device type, as well as the individual patient risk of ischemic versus hemorrhagic complications.

AB - Dual antiplatelet therapy reduces the risk of myocardial infarction, stent thrombosis, and cardiovascular mortality after percutaneous coronary intervention, but the optimal duration of therapy remains unclear. Stent thrombosis, one of the most feared complications of coronary intervention, is associated with high mortality and morbidity and is related in part to technical and patient-specific factors. Advances in device technology and better understanding of the pathophysiology of stent thrombosis have reduced the frequency of this devastating complication. Bioresorbable vascular scaffolds possess a number of advantageous features and are currently undergoing active investigation. Bioresorbable vascular scaffolds have been demonstrated to restore physiologic vasomotion, allow for late lumen enlargement, and upon full resorption remove the nidus for very late polymer reactions and resolve concerns of stent malapposition and side branch jailing. Based on the results from recent large-scale randomized trials, the optimal duration of dual antiplatelet therapy may depend on the choice of device type, as well as the individual patient risk of ischemic versus hemorrhagic complications.

KW - Bioresorbable vascular scaffolds

KW - Dual anti-platelet therapy

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84939122890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939122890&partnerID=8YFLogxK

U2 - 10.1002/ccd.26099

DO - 10.1002/ccd.26099

M3 - Article

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

ER -